ReviewBiology of sex differences2026
Sex differences in MASLD-related atherosclerosis: plaque phenotype, vascular dysfunction, and cardiovascular outcomes.
Review in Biology of sex differences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Emerging evidence suggests that the vascular manifestations of MASLD differ substantially between men and women. We therefore hypothesized that the mechanisms, plaque phenotypes, and clinical implications of MASLD-related ASCVD are sex-specific. METHODS AND
resultsIn this narrative review, we searched PubMed/MEDLINE for studies published up to April 2026 and synthesized current evidence regarding sex differences in MASLD-related atherosclerosis. Available data support a sex-specific vascular paradigm in MASLD. In men, MASLD is more strongly associated with calcified and obstructive coronary atherosclerosis. In contrast, women with MASLD more frequently exhibit non-calcified atherosclerotic phenotypes and functional vascular abnormalities (e.g., endothelial dysfunction, arterial stiffness, and coronary microvascular dysfunction). Importantly, despite lower coronary artery calcium (CAC) burden, women with MASLD experience a disproportionately greater risk of adverse cardiovascular events. Therefore, calcification-centered assessment may inadequately capture ASCVD risk in women with MASLD by failing to identify non-calcified plaque and functional vascular abnormalities. These sex differences are likely mediated by interacting pathobiological and socio-cultural factors, including sex hormones and menopausal transition, adipose tissue distribution, immune-metabolic and inflammatory profiles, genetic susceptibility, and gender influences.
conclusionMASLD is associated with distinct sex-specific cardiovascular phenotypes that have important clinical implications for ASCVD risk assessment and prevention. Women with MASLD may develop clinically significant ASCVD despite lower CAC burden, supporting a sex- and menopause-aware approach to cardiovascular evaluation. In selected high-risk women, complementary use of multimodality imaging beyond CAC may improve risk stratification and facilitate earlier detection of clinically relevant cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.